Curis Inc
NASDAQ:CRIS
| Market Cap (Intraday) | 354.84M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.89 |
| 50-Day MA | $4.89 |
| 200-Day MA | $8.10 |
Curis Inc Stock, NASDAQ:CRIS
128 Spring Street, Building C, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.503.6500
Number of Employees: 28
Description
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.